P. Jänne

Overcoming EGFR Resistance by Monovalent and Bident Inhibitors Targeting Cys775

Covalent targeting of EGFR cysteine 797 by osimertinib is one of the most successful breakthroughs in targeted therapy, fundamentally transforming the treatment landscape for non-small-cell lung cancer (NSCLC) patients. However, resistance driven by the mutation of C797 remains a major clinical challenge. Developing...

Tumor mutational burden as a predictor of immune-related adverse events in patients with advanced non-small cell lung cancer receiving immune checkpoint inhibitors: a Brief Report.

BACKGROUND Tumor mutational burden (TMB) has been established as a predictor of response to immune checkpoint inhibitors (ICI) ± chemotherapy in advanced non-small cell lung cancer (NSCLC). However, less is known about its role as a predictor of immune-related adverse events (irAEs) METHODS: This monocentric cohort stu...

Germline EGFR T790M mutation and lung cancer risk.

PARP inhibition enhances the antitumor activity of HER3-DXd in non-small cell lung cancer

It is suggested that combining HER3-DXd with PARP inhibitors with a significant synergy is observed with PARP inhibitors, effective in both EGFR- and KRAS-mutated NSCLC models, effectively targeting diverse NSCLC subtypes.

Germline determinants of risk and molecular subtype in young-onset lung cancer

A complex germline architecture underlying susceptibility and molecular subtype in young-onset lung cancer is delineated, consistent with additive risk from rare and common variants.

Therapeutic targeting of RAS-mediated resistance in oncogene-driven lung cancer.

RAS alterations mediate resistance to targeted agents in approximately 10% of oncogene-driven lung cancer, and Rational combinations with novel RAS inhibitors are effective in preclinical models, providing the basis for their clinical investigation and extending the paradigm of precision oncology.